SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending amidst a robust multi-year deal to supply AI chips to Meta Platforms, signaling the company's strong position in the diversifying AI infrastructure market. The community is actively discussing AMD's competitive advantage and strategic investments like the Crusoe loan, reinforcing its role as a key player in powering future AI growth.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as its strategic pivot to an AI/HPC data center development company gains significant market attention, underscored by its rebrand to Cipher Digital and a major sale of Bitcoin mining assets. The community is actively discussing its undervalued status and potential rerating as stable, long-term contracts with hyperscale customers position it for future growth, despite short-term volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is actively trending ahead of its highly anticipated earnings report, with significant community debate around continued insatiable AI chip demand and a potentially sold-out product pipeline, contrasted by some investors anticipating a 'sell the news' reaction and observing rising competition.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is actively discussed following news of significant multi-year agreements with both Nvidia and AMD for AI chips; bulls view these massive investments as a strategic move to dominate the AI landscape, while bears express concern over escalating capital expenditures impacting profitability amid market volatility and ongoing regulatory scrutiny.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following its recent corporate update and strong financial results, highlighted by a major global collaboration with Astellas for its VIR-5500 prostate cancer program, which includes substantial upfront payments and significant milestone potential. Community discussion is actively debating the new cash influx, promising early clinical data, and potential for a short squeeze, while others predict a 'rug pull' based on the stock's historical tendency for gains to reverse.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is generating significant buzz following robust revenue growth for ANKTIVA and an ambitious plan to expand its BioShield platform across multiple cancer indications and global markets. The community is actively discussing the potential for a substantial short squeeze, propelled by strong bullish sentiment and anticipation of further positive catalysts.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean is trending as investors react to its latest earnings report, which showcased accelerating revenue growth guidance for 2026 and 2027, robust expansion in AI workloads, and a successful shift towards larger enterprise customers. The community is actively discussing DOCN's enhanced position as a crucial AI inference and cloud infrastructure provider, fueling a strong re-evaluation of its growth trajectory.

The AES Corp. engages in the provision of power generation and utility services through its renewable and thermal generation facilities and distribution businesses. It operates through the following segments: U.S. and Utilities Strategic Business Unit (SBU), South America SBU, MCAC SBU, Eurasia SBU. The U.S. and Utilities SBU segment consists of facilities in the United States, Puerto Rico and El Salvador. The South America SBU segment covers Chile, Colombia, Argentina, and Brazil. The MCAC SBU segment refers to Mexico, Central America, and the Caribbean. The Eurasia SBU segment handles operations in Europe and Asia. The company was founded by Dennis W. Bakke and Roger W. Sant in 1981 and is headquartered in Arlington, VA.

AES Corp.

AES Corporation is trending amid widespread reports that BlackRock's Global Infrastructure Partners is nearing a multi-billion-dollar takeover, a move seen to capitalize on the utility's strategic position in supplying renewable energy to fast-growing tech and AI data centers. The community is intensely debating the potential acquisition price, weighing the company's significant debt against its long-term growth prospects and perceived undervaluation.

GraniteShares ETF Trust - GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Long AMD Daily ETF

AMDL is gaining attention due to positive developments for its underlying AMD, including a $1 billion Department of Energy partnership, an export license for AI chips to China, and an analyst upgrade citing sold-out server chips for 2026. The community is keenly discussing whether recent pullbacks are 'manipulation' or opportune entry points, given AMD's strong position in the expanding AI sector.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to recent FDA clearance for commercial GP2 supply and confirmation of funding through 2026, significantly de-risking its late-stage breast cancer immunotherapy. The community is buzzing about two abstracts accepted for the upcoming AACR meeting, with high insider ownership fueling speculation for a potential partnership or buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;</li><li>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.</li><li>Cassava previously reached a settlement with the SEC regarding the allegations and paid a monetary penalty without admitting or denying the SEC’s allegations.</li></ul>&nbsp;Cassava Sciences, Inc. (SAVA) said on Thursday that the U.S. Department of Justice has closed its probe into the company over allegations of research misconduct pertaining to its drug Simufilam.The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” &nbsp;CEO Richard J. Barry said.Shares of the company traded 2% lower at the time of writing.<h2 class="st-heading-2">Settlement With SEC</h2>Previously in Sept. 2024, Cassava reached a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the allegations and paid a monetary penalty without admitting or denying the claims. &nbsp;The SEC charged Cassava and two former executives — founder and former CEO Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns — with making misleading statements in 2020 regarding the results of a clinical trial for their experimental Alzheimer's treatment, Simufilam.The regulator alleged that the company claimed the drug "significantly improved patient cognition," while failing to disclose that full patient data showed "no measurable cognitive improvement" in episodic memory.Hoau-Yan Wang, a professor at the City University of New York Medical School, who worked with Cassava to develop the drug, was also charged with manipulating trial data.<h2 class="st-heading-2">Simufilam Now</h2>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.The decision to discontinue the Alzheimer’s program followed the drug’s failure to show clinical benefit in a late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume improved from ‘low’ to ‘normal’ levels.A Stocktwits user expressed doubts regarding the allegations raised against the company and said they will not invest in it again.<stembedurl>https://www.stocktwits.com/2bitinvestor/message/645330236</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/btm-stock-falls-reverse-split/cZRkTKdR4D4">BTM Stock Pares Early Losses After Company Announces 1-For-7 Reverse Stock Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration a Cassava Sciences, Inc. logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program

The probes into the company by both the DOJ and the SEC have now been closed. 

Equity

Cassava Sciences (NASDAQ:SAVA) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised Cassava Sciences from a "sell" rating to a "hold" rating in a report on Sunday...

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO...

Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Trading Down 23.9% - Here's What Happened...

<ul class="summary-bullets"><li>Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency.</li><li>The company added that it no longer expects to initiate the trial in question in the first half of 2026.&nbsp;</li><li>Cassava discontinued Simufilam’s study in mild-to-moderate Alzheimer’s disease in March.</li></ul> Shares of Cassava Sciences, Inc.’s slid a deep 24% on Friday after the U.S. Food and Drug Administration placed a full clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy.The stock is now on track for its worst day in about 9 months.The company was informed by the FDA of the hold in a letter earlier this week, it said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069530/000143774925038313/sava20251218_8k.htm">filing</a> with the Securities and Exchanges Commission. The company now has to provide the agency with additional information, including additional pre-clinical data, and modify the protocol design.Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the first half of 2026.The company failed to provide a new timing for the study, and said it would depend on its ability to provide the requested information and on satisfactory completion of FDA’s review.<h2 class="st-heading-2">Cassava Hits Multiple Roadblocks With Simufilam</h2>Cassava <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-drops-over-30-percent-after-drug-fails-study/ch7yzVjRbdz">discontinued</a> Simufilam’s study in mild-to-moderate Alzheimer’s disease in March after the drug did not fare better than placebo in reducing cognitive or functional decline in a late-stage study. The company discontinued its efforts to develop the drug for Alzheimer’s disease and phased out the program and then committed to evaluating the drug’s potential in TSC-related epilepsy.Tuberous Sclerosis Complex (TSC) is a rare genetic disorder causing non-cancerous tumors (hamartomas) to grow in many organs, primarily the brain, skin, kidneys, heart, lungs, and eyes. It can lead to symptoms including seizures, developmental delays, intellectual disabilities, and skin abnormalities.According to Austin-based Cassava, TSC affects nearly 50,000 people in the US and epilepsy is one of the most common neurological features of TSC, occurring in 84% of patients. Current therapies for the condition include antiepileptic drugs and mTOR inhibitors which are not fully effective, and are associated with serious adverse events, the company said in November.Cassava decided to study Simufilam in TSC-related epilepsy on the results of two sophisticated studies conducted in animals that support the drug’s potential, CEO Rick Barry said last month. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA fell from ‘bearish’ to ‘extremely bearish' territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user highlighted a buying opportunity.<stembedurl>https://www.stocktwits.com/MrStockxy/message/639701864</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 8% this year and by 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-heads-for-its-best-day-in-over-8-months-rally-isn-t-only-about-trump/cLe0GDaREst">Rocket Lab Stock Heads For Its Best Day In Over 8 Months — And The Rally Isn’t Only About Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?

FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.

FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold

Cassava Sciences confirms an FDA clinical hold on its simufilam epilepsy trial, delaying plans and requiring more data despite strong cash reserves.read more...

Cassava Sciences (NASDAQ:SAVA) CEO Purchases $201,808.75 in Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction that occurred on Wednesday, November 19th. The stock was bought...

Cassava Sciences Sees Unusually High Options Volume (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 8,896 call options on the company. This represents an...

Insider Buying: Cassava Sciences (NASDAQ:SAVA) CEO Acquires 73,385 Shares of Stock

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 73,385 shares of the business's stock in a transaction on Wednesday, November 19th. The stock was bought at an average...

Cassava Sciences (NASDAQ:SAVA) Trading Down 3% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Shares Down 3% - Time to Sell...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAVA News

SAVACassava Sciences Inc